Last reviewed · How we verify
Combination of treatments
Combination of treatments is a Small molecule drug developed by Milton S. Hershey Medical Center. It is currently in Phase 2 development. Also known as: Orlistat, Alli, OCP, Oral Contraceptive.
A combination therapeutic approach designed to enhance treatment efficacy through synergistic mechanisms, though the specific components are not publicly detailed.
At a glance
| Generic name | Combination of treatments |
|---|---|
| Also known as | Orlistat, Alli, OCP, Oral Contraceptive, Weight Loss |
| Sponsor | Milton S. Hershey Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
This is a Phase 2 combination treatment under investigation at Milton S. Hershey Medical Center. Without disclosure of the specific drugs or mechanisms being combined, the exact synergistic approach cannot be determined. Combination therapies typically work by targeting multiple pathways simultaneously to improve clinical outcomes.
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Effects of Percutaneous Electrical Stimulation in Patients With Chronic Supraspinatus Tendinopathy (NA)
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination of treatments CI brief — competitive landscape report
- Combination of treatments updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI
Frequently asked questions about Combination of treatments
What is Combination of treatments?
How does Combination of treatments work?
Who makes Combination of treatments?
Is Combination of treatments also known as anything else?
What development phase is Combination of treatments in?
Related
- Manufacturer: Milton S. Hershey Medical Center — full pipeline
- Also known as: Orlistat, Alli, OCP, Oral Contraceptive, Weight Loss
- Compare: Combination of treatments vs similar drugs
- Pricing: Combination of treatments cost, discount & access